Biomaterial Database

New trends in maintenance immunosuppression. 1997

H Isoniemi

Department of Surgery, Helsinki University Central Hospital, Finland.

Maintenance immunosuppression in solid organ transplantation has been restricted to three drugs for many years, corticosteroids, azathioprine and cyclosporine. There has been need for more selective drugs with better ratio of efficacy to side effects. During the last decade a variety of new immunosuppressive agents has been under development and some of them are now at hand.

UI	MeSH Term	Description	Entries
D007165	Immunosuppression Therapy	Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.	Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166	Immunosuppressive Agents	Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.	Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D004359	Drug Therapy, Combination	Therapy with two or more separate preparations given for a combined effect.	Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006084	Graft Rejection	An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.	Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Isoniemi

New trends in immunosuppression.

January 2005, International immunopharmacology,

H Isoniemi

New trends in immunosuppression.

June 2000, Drugs of today (Barcelona, Spain : 1998),

H Isoniemi

New trends in clinical immunosuppression.

December 1994, Transplantation proceedings,

H Isoniemi

New trends in immunosuppression and immunotherapy.

December 2006, International immunopharmacology,

H Isoniemi

New trends in immunosuppression in transplant patients.

January 2000, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,

H Isoniemi

New trends in immunosuppression for renal transplantation.

November 1994, Current opinion in nephrology and hypertension,

H Isoniemi

New trends in non-antigen-specific immunosuppression.

March 1979, Transplantation proceedings,

H Isoniemi

Maintenance immunosuppression: new agents and persistent dilemmas.

April 2000, Advances in renal replacement therapy,

H Isoniemi

Maintenance immunosuppression.

January 2001, Clinical transplants,